In This Article:
- Expected to enhance visibility and access to U.S. investors
- Trading to commence on March 6, 2025
TORONTO, March 06, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTCQB: CNVIF) (“Conavi Medical” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that its common shares have been approved for uplisting from the OTC Pink Open Market to the OTCQB Venture Market, with trading set to commence on March 6, 2025. The ticker symbol will remain CNVIF, and no action is needed by shareholders. Trading on the OTCQB is expected to complement the Company's existing listing on the TSX Venture Exchange.
“As we move toward commercial launch of our next-generation Novasight system, we’re pleased to increase investor transparency and visibility with this uplisting,” said Thomas Looby, Conavi Medical’s CEO. “We believe this step will increase our exposure to the U.S. investment community and broaden our investor base.”
Operated by the OTC Markets Group, the OTCQB Venture Market is a U.S. trading platform designed for developing and entrepreneurial-stage companies. The Securities and Exchange Commission considers the OTCQB to be an “established public market” for determining the public market price when registering securities for resale. Companies listed on the OTCQB are current in their reporting and undergo an annual verification and management certification process. Additional information about the OTC Markets Group Inc. and the OTCQB can be found at otcmarkets.com.
About Conavi Medical
Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China’s National Medical Products Administration, and Japan’s Ministry of Health, Labor and Welfare. For more information, visit conavi.com.
Cautionary Statement Regarding Forward-Looking Information
This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws, which reflect the current expectations of management of Conavi’s future growth, results of operations, performance and business prospects and opportunities. Forward-looking statements are frequently, but not always, identified by words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions, although these words may not be present in all forward-looking statements. Forward-looking statements that appear in this release may include, without limitation, references to Conavi’s plans for the commercialization of its Novasight Hybrid™ System.